Ignite Creation Date:
2024-05-06 @ 4:01 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04849273
Status:
TERMINATED
Last Update Posted:
2023-05-26
First Post:
2021-04-12
Brief Title:
A Study of TPX-0131 a Novel Oral ALK Tyrosine Kinase Inhibitor in Patients With ALK Advanced or Metastatic NSCLC
Sponsor:
Turning Point Therapeutics Inc
Organization:
Turning Point Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-28
Start Date Type:
ACTUAL
Primary Completion Date:
2023-04-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-04-18
Completion Date Type:
ACTUAL
First Submit Date:
2021-04-12
First Submit QC Date:
April 16 2021
Study First Post Date:
2021-04-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-24
Last Update Post Date:
2023-05-26
Last Update Post Date Type:
ACTUAL